# Cell-Penetrating Peptides Delivering siRNAs: An Overview 细胞穿透肽递送siRNA的策略进展：靶向递送与临床应用前景

Luca Falato, Maxime Gestin and Ülo Langel

## Abstract 摘要

Cell-Penetrating Peptides (CPP) are valuable tools capable of crossing the plasma membrane to deliver therapeutic cargo inside cells. Small interfering RNAs (siRNA) are double-stranded RNA molecules capable of silencing the expression of a specific protein triggering the RNA interference (RNAi) pathway, but they are unable to cross the plasma membrane and have a short half-life in the bloodstream. In this overview, we assessed the many different approaches used and developed in the last two decades to deliver siRNA through the plasma membrane through different CPPs sorted according to three different loading strategies: covalent conjugation, complex formation, and CPP-decorated (functionalized) nanocomplexes. Each of these strategies has pros and cons, but it appears the latter two are the most commonly reported and emerging as the most promising strategies due to their simplicity of synthesis, use, and versatility. Recent progress with siRNA delivered by CPPs seems to focus on targeted delivery to reduce side effects and amount of drugs used, and it appears to be among the most promising use for CPPs in future clinical applications.

<span style=color:blue>细胞穿透肽（CPP）是一类能够穿越细胞膜并将治疗性载荷输送至细胞内部的重要工具。小干扰RNA（siRNA）是双链RNA分子，能够通过激活RNA干扰（RNAi）途径来特异性沉默目标蛋白的表达。然而，siRNA本身无法穿透细胞膜，且在血液中的半衰期较短。在本综述中，我们回顾了过去二十年中，针对如何通过不同的细胞穿透肽将siRNA有效递送至细胞膜内所采用和发展的多种策略，并根据三种不同的负载策略对这些方法进行了分类：共价连接、复合物形成以及CPP修饰（功能化）纳米复合物。每种策略都有其优缺点，但后两者因其合成简便、应用灵活且具有较高的通用性，已成为当前最常报道和最具潜力的策略。近期的研究进展表明，利用CPP递送siRNA的应用重点逐渐转向靶向递送，以减少副作用并降低药物用量，这使得CPP在未来的临床应用中展现出极大的前景。</span>

## 1 Cell-Penetrating Peptides 细胞穿透肽

### 1.1 Introducing Cell-Penetrating Peptides 细胞穿透肽简介

Cell-penetrating peptides (CPPs) are a group of linear and branched peptides that are usually between 5 and 30 residues and capable of passing through the plasma membrane. They can involve non-proteogenic amino acids (e.g., ornithine) or chemically modified residues in their structure that enhance endosomal escape, reduce degradation from endocytic proteases, and change the net charge, but their sequence is mainly composed of proteogenic amino acids. In addition to the main sequence, a polymer (e.g., PEG) or a fatty acid can be conjugated via a covalent bond to the peptide’s backbone to modify its physical-chemical properties. Some have a biological effect but they are mostly intended as carriers; in fact, they are capable of delivering therapeutic cargos through the plasma membrane.

<span style=color:blue>细胞穿透肽（CPPs）是一类通常由5到30个氨基酸残基组成的线性或分支肽链，能够跨越质膜。它们的结构中可能包含非蛋白质氨基酸（如鸟氨酸）或经过化学修饰的氨基酸残基，这些改性有助于增强内吞体逃逸、减少内吞酶的降解作用，并改变肽分子的净电荷，但其基本序列主要由标准蛋白质氨基酸构成。除了主要序列外，聚合物（如聚乙二醇，PEG）或脂肪酸可通过共价键与肽链骨架连接，从而调节其物理化学性质。虽然一些细胞穿透肽具有生物学效应，但它们大多作为载体使用，能够有效地将治疗性载荷递送穿越细胞膜。</span>

CPPs have some standard features in common, such as positively charged residues (e.g., arginine and lysine) and amphipathicity. These physical-chemical properties and their distribution along the peptide molecule are associated with effects on the cellular machinery and the uptake mechanism, and thus they are usually used as a classifying method for CPPs. An alternative method of classification divides CPPs into groups according to the strategy used to conjugate the cargo and the carrier: peptides linked to the cargo by a covalent bond, and peptides stably complexed with it.

<span style=color:blue>细胞穿透肽（CPPs）具有一些共通的标准特征，如正电荷氨基酸残基（如精氨酸和赖氨酸）以及两性性质。这些物理化学特性及其在肽分子中的分布与细胞内的作用机制和细胞摄取机制密切相关，因此，通常依据这些特征对CPPs进行分类。另一种常见的分类方法则是根据载荷与载体结合的策略，将CPPs划分为两类：一类是通过共价键与载荷连接的肽，另一类是与载荷稳定复合的肽。</span>

Despite significant research on CPPs, there are still some gray areas such as the uptake mechanism, discussed below. Currently, there are approximately 1850 CPPs available, but although the first clinical trial of a CPP was in 2000 and some are currently undergoing clinical trials for anticancer therapies, FDA (US Food and Drug Administration) approved CPP or CPP-related therapy are still lacking.

<span style=color:blue>尽管关于细胞穿透肽（CPPs）的研究取得了显著进展，但仍存在一些未解之谜，尤其是在其摄取机制方面，下面将进行讨论。目前，已有约1850种CPP可供选择，尽管自2000年首次进行CPP临床试验以来，且部分CPP正在进行抗癌治疗的临床试验，但FDA（美国食品药品监督管理局）尚未批准任何CPP或相关疗法。</span>

Among the reasons for this disparity between available peptides and lack of clinical trials are in vivo stability issues due to proteolytic degradation, immunogenicity, lack of specificity, and reduced efficiency due to the still not fully clarified uptake and endosomal escape mechanisms. For these reasons, recent research is focused on the development of more stable CPPs (e.g., using D-amino acids) and CPP-based nanoparticles capable of higher specificity and enhanced uptake.

<span style=color:blue>这种可用肽与临床试验缺乏之间的差异，主要归因于其体内稳定性问题，如酶解降解、免疫原性、特异性不足，以及由于摄取和内体逃逸机制尚未完全阐明而导致的效率下降。因此，近期的研究重点在于开发更为稳定的CPP（如使用D-氨基酸）以及具有更高特异性和增强摄取能力的CPP基纳米颗粒。</span>

### 1.2 Uptake Mechanisms and Endosomal Escape 摄取机制和内体逃逸

Currently, the endocytosis is considered the primary uptake mechanism for CPPs (Fig. 1), and direct translocation is believed to be one of the possible internalization pathways depending on administration method and concentration.

<span style=color:blue>目前，内吞作用被认为是细胞穿透肽（CPPs）的主要摄取机制（见图1），而直接转位则被认为是另一种可能的内化途径，这取决于给药方式和药物浓度。</span>

![485053_1_En_18_Fig1_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_18_Fig1_HTML.png)

**Fig. 1** Different uptake mechanisms of nanoparticles

Endocytosis is an energy-dependent mechanism usually divided into three distinct processes<span style=color:blue>内吞作用是一种依赖能量的机制，通常可分为以下三种不同的过程</span>:

1. Caveolae-mediated endocytosis, as caveolae are considered to be a specialized and morphologically distinguishable form of lipid raft, and are a bulb-shaped invagination of the plasma membrane. These plasma membrane rafts are usually coated with receptors able to bind to lipid chains, such as heparan sulfate proteoglycans (HSPGs) and class-A scavenger receptors (SCARA). The latter have been shown to have an essential part in caveolae-mediated uptake of several CPP:ON complexes.<span style=color:blue>**洞窟介导的内吞作用**：洞窟被认为是脂质筏的一种特殊形式，具有形态学上的可区分性，是细胞膜的一个球状内陷结构。这些脂质筏通常被能够与脂质链结合的受体覆盖，如肝素硫酸蛋白多糖（HSPGs）和A类清道夫受体（SCARA）。研究表明，后者在多种CPP:ON复合物的洞窟介导摄取过程中起着至关重要的作用。</span>
2. Clathrin-mediated endocytosis (CME) is the process by which proteins and lipids are removed from the plasma membrane. Clathrin is a tri-legged structured protein characterized by the presence of three heavy and three light chains. Its shape allows it, when recruited, to deform the membrane within a cage-like structure consisting of 12 pentagons and a variable number of hexagons, forming an invagination that results in a “clathrin-coated vesicle.” The resulting intracellular vesicles go toward an un-coating process before fusing with endosomes. A recent paper reported that Syndecan-4, one of the heparan sulfate proteoglycans, is a primary cell surface target for arginine-rich peptides that lead to clathrin-mediated endocytosis of the CPP.<span style=color:blue>**网格蛋白介导的内吞作用（CME）**：这是一个通过网格蛋白从细胞膜移除蛋白质和脂质的过程。网格蛋白由三条重链和三条轻链组成，其三足结构使其能够招募并改变膜的形状，形成由12个五边形和若干六边形构成的笼状结构，从而内陷形成“网格蛋白包被小泡”。这些胞内小泡会经历去包被过程，然后与内体融合。最近的研究表明，肝素硫酸蛋白多糖之一的Syndecan-4是富含精氨酸的肽的主要细胞表面靶标，能够引发网格蛋白介导的CPP内吞。</span>
3. Macropinocytosis (MPC) consists of the uptake of extracellular material via the formation of protrusions or blebs extending from the cell membrane, folding backward around the particles and trapping them into macropinosomes. Macropinocytosis can be defined as a clathrin-independent form of endocytosis. The generation of the protrusion and the regulation of the macropinocytic flow has been the subject of recent intensive studies because of its importance in several diseases, such as the cell-to-cell transmission of prions, pathogenesis of atherosclerosis, and cancer. MPC is very likely involved in CPPs uptake due to its capacity to enable the internalization of a large volume of extracellular fluid into cells. To confirm the relation between particle size and uptake mechanism, Nakase et al. recently reported enhanced uptake of extracellular vesicles decorated (functionalized) with arginine-rich CPPs by stimulation of macropinocytosis-related receptors.<span style=color:blue>**大吞噬作用（MPC）**：此过程通过细胞膜上形成突起或泡状物来摄取细胞外物质，突起物向后折叠并围绕粒子形成大吞噬小体。大吞噬作用被定义为一种网格蛋白非依赖的内吞作用。由于其能够内化大量细胞外液体，MPC在多种疾病中（如朊病毒的细胞间传播、动脉粥样硬化和癌症等）具有重要意义。MPC很可能参与CPP的摄取。Nakase等人最近的研究表明，刺激与大吞噬作用相关的受体，可以增强富含精氨酸的CPP修饰细胞外小泡的摄取。</span>
4. A CPP:cargo complex, after entering the cell, can be entrapped in an endosome and degraded after the fusion with the lysosome. Currently, several strategies are available to promote endosomal escape, including (i) conjugating an agent that inhibits acidification of the endosome to the peptide, e.g., trifluoromethylquinoline, (ii) endowing the peptides of protonable moieties such as histidine, taking advantage of the “proton sponge effect”, (iii) stearylation, which has been shown to be a valuable strategy but is more effective on some peptides than others, (iv) synthesizing peptides that can change their secondary structure according to the pH, assuming an alpha-helix structure at the lower pH of the late endosomes, to destabilize the membrane. Algayer et al. reported an extensive structure-activity relationship (SAR) study beginning at the INF7-Tat sequence. Despite efforts thus far, the structure/sequence-activity relation is not yet fully understood. Even the slightest change in the sequence, or the same modification on different peptides, such as stearylation, can considerably impact endosomal escape capacity and delivery effectiveness. <span style=color:blue>在CPP:负载复合物进入细胞后，可能会被困在内体中，并在与溶酶体融合后被降解。为了促进内体逃逸，已有多种策略被提出，包括：（i）将抑制内体酸化的试剂（如三氟甲基喹啉）共轭到肽上；（ii）赋予肽可质子化的基团（如组氨酸），利用“质子海绵效应”；（iii）硬脂酰化，这一策略已被证明在某些肽中效果较好；（iv）合成能够根据pH值变化其二级结构的肽，利用其在内体低pH下形成α螺旋结构来 destabilize膜结构。Algayer等人开展了从INF7-Tat序列起始的结构-活性关系（SAR）研究。尽管取得了诸多进展，但结构/序列-活性关系仍未完全明了。即使是微小的序列变化或相同的修饰（如硬脂酰化）对不同的肽，也可能大幅度影响内体逃逸的能力和递送效果。</span>

## 2 Small Interfering RNA 小干扰RNA

### 2.1 A Brief Introduction to Small Interfering RNAs siRNA简介

Small interfering RNAs (siRNAs) are a class of double-stranded RNA of 21 to 23 nucleotides with two overlapping nucleotides at the 3′ ends. They can virtually block the expression of any protein on a transcriptional level through the RNA interference (RNAi) pathway by interaction with the RNA-induced silencing complex (RISC) present in the cytoplasm. This complex escorts one preferentially loaded single strand RNA (guide strand) to the complementary mRNA and then an endonuclease present in the complex cleaves the target mRNA. An exogenous siRNA can be delivered in the cytoplasm, activating the RISC complex to silence a target mRNA. Currently, delivery of siRNAs into cells remains a primary obstacle to the full expression of potential siRNA therapies.

<span style=color:blue>小干扰RNA（siRNA）是一类由21到23个核苷酸组成的双链RNA，3'末端有两个重叠的核苷酸。它们通过与细胞质中的RNA诱导沉默复合物（RISC）相互作用，几乎可以在转录水平上阻断任何蛋白质的表达。RISC复合物将一个优先加载的单链RNA（引导链）引导至与之互补的mRNA，然后复合物中的内切酶会切割目标mRNA。外源性siRNA可以被递送到细胞质中，激活RISC复合物以沉默目标mRNA。目前，将siRNA有效递送到细胞内仍然是充分发挥siRNA治疗潜力的主要障碍。</span>

### 2.2 Delivery Methods 递送方法

Small interfering RNAs are unable to cross the cell membrane or survive in the bloodstream without being immediately degraded. Therefore, to be protected and effective, they need a carrier. The most commonly employed vehicle in research today are liposomes, such as lipofectamine, which consists of positively charged liposomes able to form complexes with the negatively charged siRNA. Polymers of various lengths, such as polyethylene glycol, are, in some cases, conjugated covalently to the siRNA to shield it from degradation. Inorganic nanoparticles are also employed as delivery systems, e.g., metals, metal oxides, carbon material, nano-diamonds, and magnetic nanoparticles (super-paramagnetic iron oxide nanoparticles). Among the plethora of nanocarriers for siRNA delivery, peptides have gained popularity because of their structural and functional diversity. A broad variety of peptides can translocate siRNA into living cells via different pathways. CPPs can be used to deliver siRNA in cells in vitro and in vivo in the form of nanoparticles covalently conjugated or non-covalent complexes, and have recently been used to functionalize nanoparticles to enhance the uptake and the specificity of the delivery (Fig. 2).

<span style=color:blue>小干扰RNA（siRNA）无法穿越细胞膜，也无法在血液中存活而不被立即降解。因此，为了保护和提高其效力，siRNA需要借助载体。目前，研究中最常用的载体是脂质体，如脂质转染试剂（lipofectamine），它由带正电荷的脂质体组成，能够与带负电荷的siRNA形成复合物。在某些情况下，聚合物（如聚乙二醇）被共价结合到siRNA上，以保护其免受降解。无机纳米粒子也被用作递送系统，例如金属、金属氧化物、碳材料、纳米金刚石和磁性纳米粒子（超顺磁性铁氧化物纳米粒子）。在众多用于siRNA递送的纳米载体中，肽类因其结构和功能多样性而受到广泛关注。多种肽类可以通过不同途径将siRNA转运到活细胞中。细胞穿透肽（CPP）可用于将siRNA递送到体外和体内细胞，形式可以是共价结合的纳米粒子或非共价复合物，近年来也被用于功能化纳米粒子，增强递送的摄取量和特异性（图2）。</span>

![485053_1_En_18_Fig2_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_18_Fig2_HTML.png)

**Fig. 2** Three strategies for siRNA delivery using CPPs. (**a**) cargo covalently conjugated to the CPP, (**b**) cargo complexed with the CPP, and (**c**) nanoparticle decorated with CPPs

## 3 Delivering siRNA Using CPPs: Three Strategies 使用CPP递送siRNA的三种策略

### 3.1 CPP Covalently Conjugated to siRNA (CPP-siRNA) CPP与siRNA的共价结合（CPP-siRNA）

An early strategy to covalently conjugate CPP to the siRNA utilized a covalent bond, which ensures proximity between the CPP and its cargo, prevents their separation in medium in vitro and in the bloodstream in vivo within a range of environmental conditions (presence or absence of certain enzymes and pH value), and potentially reduces the toxicity of the CPP due to the lower molar ratio needed. Most of the time, the CPP and its cargo are bonded together via a cleavable linker that allows the components to be separated in the cytoplasm and the siRNA to be recruited by the RISC complex, avoiding localization in the nucleus where it is ineffective. One of the most popular linkers for covalently conjugated CPP-siRNA is disulfide linkage, which is cleavable in the reducing environment of the cytoplasm, e.g., by glutathione. Muratovska et al. conjugated penetratin to siRNA via disulfide linkage and achieved downregulation of a luciferase reporter gene to a level comparable to cationic liposomes. A similar result was reported by Davidson et al..

<span style=color:blue>将CPP与siRNA共价结合的早期策略利用了共价键，这确保了CPP与其载荷之间的接近性，防止了它们在体外培养基和体内血液中因环境条件（如某些酶的存在与否以及pH值的变化）而分离，并可能由于所需的较低摩尔比而减少CPP的毒性。通常，CPP与其载荷通过可裂解连接子结合在一起，这种连接子可以在细胞质中使组件分离，从而将siRNA招募到RNA诱导沉默复合物（RISC），避免其进入核内而失去活性。最常用的共价结合CPP-siRNA的连接子是二硫键，该键可以在细胞质的还原环境中裂解，例如通过谷胱甘肽的作用。Muratovska等人通过二硫键将penetratin与siRNA结合，并实现了对荧光素酶报告基因的下调，效果与阳离子脂质体相当。Davidson等人也报告了类似的结果。</span>

On the other hand, the non-covalent complex penetratin:siRNA, despite good uptake, resulted in low downregulation due to entrapment in endosomes/lysosomes, because the peptide cannot show its endosomolytic properties when complexed with the cargo. However, when Moschos et al.  purified the covalently conjugated penetratin-siRNA (and TAT-siRNA) via HPLC, they achieved only moderate suppression of the reporter gene even at high concentrations of peptide, raising the possibility that the knockdown effect is induced by siRNA complexed with the CPP (instead of conjugated), These inconsistent results have yet to be fully clarified. It is noteworthy that binding the CPP (penetratin or Tat) to the 3′ instead of the 5′ end of the siRNA strand increased the downregulation effect. An interesting attempt was made by Chiu et al. to couple Tat to the 3′ end of an siRNA molecule through the non-cleavable linker SMPB (sulfosuccinimidyl 4-(p-maleimidophenyl) butyrate). The obtained result was a rapid uptake into cells, but a dot-like distribution of the labeled siRNA suggested that this was mainly inside endosomes, and therefore not available to the silencing pathway. Nevertheless, the reduced expression of the targeted gene was achieved. Further studies suggested that the reduced expression was probably due to the siRNA complexed with Tat rather than the siRNA covalently conjugated, since the peptide linked may cause steric hindrance problems to the RISC complex; further studies are needed to confirm this hypothesis. The penetratin-siRNA covalent approach was used on neuron cells (in vitro) and on the central nervous system (in vivo) by applying the treatment directly to the target tissue. This approach had lower toxicity on the cells compared with the liposome-based siRNA application strategy. However, it is not certain if the internalization and silencing effect can be attributed to the covalently conjugated or the complexed species because there was no purification step before testing. Furthermore, application directly on the tissue could not, of course, elucidate whether the treatment could pass through the blood-brain barrier. In addition to Tat and penetratin, Ye et al. and Yu et al. developed and then improved a covalent carrier using low molecular weight protamine (LMWP) conjugated to the siRNA molecule via a cytosol-cleavable disulfide linkage using PEG as spacer. None of our experimental attempts to deliver siRNA covalently bonded to a CPP via disulfide bond have been successful (unpublished results) despite the detection of uptake. Thus, the theoretical advantages of having the carrier covalently conjugated to the carrier are not reflected in practice given the prohibitive obstacles such as synthesis and purification. The majority of the results thus far demonstrate limited success in delivery , especially in vivo.

<span style=color:blue>另一方面，尽管非共价复合物penetratin:siRNA能够有效地进入细胞，但由于被困于内体或溶酶体内，导致其下调效果较差，这是因为肽与siRNA复合后无法表现出其内体溶解特性。然而，当Moschos等人通过HPLC纯化共价连接的penetratin-siRNA（以及TAT-siRNA）时，尽管在高浓度的肽存在下，仍然只能实现适度的基因抑制效果，这表明siRNA的下调效应可能是由与CPP复合的siRNA（而非共价连接的siRNA）引起的。对于这些不一致的结果，仍然需要进一步的阐明。值得注意的是，将CPP（如penetratin或Tat）与siRNA的3′末端连接，而非5′末端，能够显著提高下调效果。Chiu等人尝试将Tat通过不可裂解连接子SMPB（磺基琥珀酰亚胺基4-(对-马来酰亚胺苯基)丁酸酯）连接到siRNA的3′末端，结果是siRNA快速进入细胞，但标记的siRNA呈现点状分布，表明这些siRNA主要位于内体中，因此无法参与沉默途径。然而，靶基因的表达却有所下降。进一步的研究表明，表达的下降可能是由于siRNA与Tat复合而非共价连接所致，因为肽与siRNA的连接可能会对RISC复合物产生空间障碍，影响其功能；这一假设仍需进一步验证。Penetratin-siRNA的共价连接方法已经在神经元细胞（体外）和中枢神经系统（体内）中进行了应用，通过将治疗直接应用于靶组织，研究表明这种方法对细胞的毒性低于传统的脂质体载体策略。然而，由于实验前没有进行纯化，尚不清楚内化和沉默效应是否来自于共价连接的复合物，还是来自与CPP复合的siRNA。此外，直接将治疗应用于组织也无法证明该方法是否能跨越血脑屏障。除了Tat和penetratin，Ye等人和Yu等人开发并改进了一种低分子量鱼精蛋白（LMWP）共价载体，通过PEG作为间隔连接子，使用可在细胞质内裂解的二硫键将其与siRNA分子连接。尽管检测到siRNA的摄取，我们所有关于通过二硫键将siRNA与CPP共价结合的实验都未能成功（未发表结果）。因此，尽管理论上将载体与载体共价结合有其优势，但在实践中却受限于合成和纯化等问题。到目前为止，大多数实验结果显示，特别是在体内，递送效果仍然有限。</span>

### 3.2 Non-covalent Complexes (CPP:siRNA) and Applications 非共价复合物（CPP:siRNA）及其应用

The complex formation strategy for the CPP and siRNA is the commonly used; indeed, the overall cationic charge of the peptide and the anionic charge of the nucleotide make this strategy much easier to perform, and is cost effective since it does not require any reaction or purification compared to the covalent bond strategy.

<span style=color:blue>CPP与siRNA的复合策略是最常见的一种方法。实际上，肽的阳电荷与核苷酸的阴电荷使得这种策略在操作上更加简便，且相比共价键策略，它具有更高的成本效益，因为不需要进行额外的化学反应或纯化步骤。</span>

The nature of the complex formation between the cationic CPPs and the anionic nucleic acid allows a versatile complex formulation using a simple “mix and incubate” technique at room temperature. However, incorporating the payload by electrostatic interaction can lead to instability and premature release of nucleic acid. To avoid this, a high density of positive charges is necessary to allow formation of stable complexes with a lower CPP concentration that will reduce toxic effects.

<span style=color:blue>阳离子CPP与阴离子核酸之间的复合关系使得可以通过简单的“混合并孵育”技术在室温下轻松形成复合物。然而，静电相互作用引入负载物可能会导致复合物的不稳定，并使核酸过早释放。为避免这种情况，需要高密度的正电荷来确保复合物的稳定性，并在较低的CPP浓度下实现这一目标，从而减少潜在的毒性。</span>

Delineating an optimal balance between peptide and siRNA, avoiding charge neutralization, and preserving a positive overall charge of the particle is mandatory to achieving uptake. Therefore, the structure of the CPP plays a crucial role in complex formation and stability. To circumvent possible charge neutralization of the CPP:siRNA complex, Endoh et al. developed a CPP by fusing U1A RNA binding protein to Tat peptide (TatU1A) that can only bind short hairpin RNA (shRNA) containing the U1A binding sequence. The complexes were able to enter the cells via endocytic pathway, and later photostimulation induced endosomal escape, allowing gene silencing. This strategy is termed CLIP-RNAi. Following the same path, Eguchi et al. developed PTD-DRBD, a Tat peptide fused with a single dsRNA binding domain(dsRBD ), and succeeded in silencing reporter genes even in difficult primary cell types (T cells, HUVECs, and hESCs) and in vivo. The dsRNA binding domain strategy was been widely studied by Tsui’s group between 2014 and 2015, synthesizing carriers using two and three CPPs fused to different DRBD domains deriving from Protein kinase R (PKR), Dicer and *E*. *coli* RNase (e.g., Hph1–Hph1-dsRBD and Tat-Tat-Tat-dsRBD) and obtaining efficient delivery of siRNA, inhibiting target gene expression with an efficiency comparable to Lipofectamine RNAi Max. Although complete binding of the siRNA required a ratio of 16:1, a slightly higher ratio of at least 20:1 was needed for effective delivery and silencing, perhaps because the two positively charged Hph1 might bind directly to the siRNA, causing a neutralization of the total charge.

<span style=color:blue>在肽与siRNA之间找到最佳的平衡点，避免电荷中和并保持颗粒的正电荷是实现有效摄取的关键。因此，CPP的结构在复合物的形成和稳定性方面起着至关重要的作用。为了防止CPP:siRNA复合物发生电荷中和，Endoh等人通过将U1A RNA结合蛋白与Tat肽（TatU1A）融合，开发了一种只能结合带有U1A结合序列的短发夹RNA（shRNA）的CPP。通过这种复合物，能够通过内吞途径进入细胞，随后利用光刺激诱导内体逃逸，进而实现基因沉默。这种策略被称为CLIP-RNAi。类似地，Eguchi等人也开发了PTD-DRBD，这是通过将Tat肽与单一双链RNA结合域（dsRBD）融合而成的载体，并成功地在一些难以处理的原代细胞（如T细胞、HUVECs和hESCs）及体内实现了报告基因的沉默。Tsui团队在2014至2015年间广泛研究了dsRNA结合域策略，合成了多个将两个或三个CPP与不同的DRBD域（来源于蛋白激酶R（PKR）、Dicer和*E. coli* RNase）融合的载体（如Hph1–Hph1-dsRBD和Tat-Tat-Tat-dsRBD），并成功地实现了siRNA的高效递送，目标基因的抑制效率与Lipofectamine RNAi Max相当。尽管完全结合siRNA需要16:1的比例，但为了有效递送和沉默，可能需要至少20:1的比例，这可能是因为两个带正电荷的Hph1可能直接与siRNA结合，导致整体电荷中和。</span>

As previously reported, the interaction between the RISC complex and siRNA is of primary importance to initiate the RNAi process, so the uptake of the complex (or conjugate) alone is not enough to achieve detectable gene silencing, and it is mandatory to promote the endosomal escape and the following release of the siRNA in the cytoplasm. EB1, a penetratin analog wherein some amino acids are replaced with histidine to induce an alpha helix structure after protonation in the acidic early-late endosomes, resulting in permeabilization of the endosomal membrane, was designed for this purpose.

<span style=color:blue>如之前所述，RISC复合物与siRNA的相互作用对启动RNAi过程至关重要，因此，仅仅是复合物的摄取并不足以实现可检测的基因沉默，必须促进内体逃逸并将siRNA释放到细胞质中。为了实现这一点，EB1作为穿透肽的一个类似物，其某些氨基酸被替换为组氨酸，以便在酸性早期-晚期内体中经过质子化后形成α螺旋结构，从而增强内体膜的通透性。</span>

PepFect6 , a stearyl-TP10 peptide (stearyl-transportan10), was designed with a pH-sensitive trifluoromethylquinoline moiety covalently incorporated in the side chain, taking advantage of the stearylation at the N′ terminus and the proton sponge effect to facilitate endosomal escape, obtaining stable RNAi responses in various cell types and in vivo (in liver). It has been reported that PepFect6 can successfully deliver even microRNAs (miRNAs) to suppress inflammation in a mouse model of irritant contact dermatitis (ICD) when pre-administered subcutaneously. MicroRNAs and silencing RNAs have similar physicochemical properties, but distinct functions. PepFect6 has been also used to develop a novel nanoparticle for siRNA delivery, as will be discussed later. Based on the PepFect6 experience, another CPP, PepFect14 (PF14) , was designed starting from the stearyl-TP10 peptide. It was built using ornithines as the main source of positive charges based on reports showing that poly-L-ornithine demonstrated superior transfection efficiency compared to equivalent poly-L-lysine-based systems relative to the ability to form more stable complexes at lower molar ratios, and on the hypothesis that ornithine might be less susceptible to proteases. Although this CPP was designed for splice correcting oligonucleotide (SCO) delivery, it has recently been used to successfully administer siRNA and was further modified with homing peptides to mediate selective transfection into glioblastoma cells.

<span style=color:blue>PepFect6是一种改良的stearyl-TP10肽（stearyl-transportan10），其设计中包含了一个pH敏感的三氟甲基喹啉基团，通过共价结合的方式融入侧链，利用N端的硬脂酰化和质子海绵效应促进内体逃逸，从而在多种细胞类型和体内（尤其是在肝脏）获得了稳定的RNAi反应。据报道，PepFect6能够在小鼠刺激接触性皮炎（ICD）模型中，通过皮下注射预先给药，成功递送微小RNA（miRNAs）来抑制炎症。尽管微小RNA和沉默RNA具有类似的物理化学特性，但其功能却有所不同。此外，PepFect6还被用来开发一种新型的纳米颗粒用于siRNA递送，稍后会详细讨论。基于PepFect6的设计经验，另一种CPP——PepFect14（PF14）也从stearyl-TP10肽出发，采用鸟氨酸作为正电荷的主要来源。研究显示，聚-L-鸟氨酸相比于聚-L-赖氨酸，能够在较低摩尔比下形成更稳定的复合物，从而表现出更高的转染效率，并且假设鸟氨酸更不易被蛋白酶降解。尽管这种CPP最初是为了递送剪接校正寡核苷酸（SCO）而设计的，但最近它已成功应用于siRNA递送，并且进一步修饰了归巢肽，帮助其实现选择性地转染到胶质母细胞瘤细胞中。</span>

NickFects are a family of branched peptides that were also developed from stearyl-TP10, modifying the sequence at Lys7 that acts as a linker between the neuropeptide galanin motif and mastoparan moiety of the peptide. NickFect70 (NF70) is a branched peptide derived from NickFect55, having a leucine substituted by an asparagine in the mastoparan region and the galanin motif substituted by a polyhistidine sequence. NF70 has three distinct segments: an N-terminal fatty acid moiety that is essential to enhance the formation of nanoparticles and stable complexes, an N-terminal hydrophobic/protonatable polyhistidine sequence that acts as a pH-sensitive switch for endosomal escape and may enhance nanoparticle accumulation in regions with lower pH (e.g., tumor tissues) in vivo*,* and a C-terminal cationic peptide. The use of NickFect70 to deliver siRNA successfully achieved gene knockdown both in vitro and in vivo.

<span style=color:blue>NickFects是一类从stearyl-TP10衍生的分支肽，这些肽通过修改Lys7序列，将其作为神经肽加拉宁结构和肽的组胺肽区域之间的连接，开发出了新的肽链。NickFect70（NF70）是从NickFect55衍生出来的分支肽，其中在组胺肽区域的亮氨酸被天冬氨酸取代，并且加拉宁结构被聚组氨酸序列替代。NF70具有三个独特的片段：一个N端的脂肪酸基团，用于增强纳米颗粒的形成和稳定复合物；一个N端的疏水/可质子化的聚组氨酸序列，作为pH敏感开关，有助于内体逃逸，并可能增强纳米颗粒在肿瘤组织等低pH区域的积累；以及一个C端的阳离子肽。通过使用NickFect70递送siRNA，成功实现了体内外的基因敲降。</span>

CADY peptide was the first secondary amphipathic CPP, and is composed of 20 residues and designed as an siRNA carrier by Crombez et al. , including amino acids such as arginine and tryptophan to improve its interaction with siRNA and with the lipid phase of the cellular membrane. The spatial conformation of CADY improves its solubility and its interaction with siRNA. A maximal knockdown of 95% was reported with reduced or no cytotoxicity. CADY:siRNA complex uptake seems to occur primarily by direct translocation, as shown by the fact that it does not co-localize with the endocytotic markers. It has been found mainly in the cytoplasm and not in vesicles, as observed with electron microscopy, confirming that the knockdown effect of the complex is not affected by the presence of endocytotic inhibitors. CADY seems to induce temporary membrane disorganization long enough to pass through the membrane, followed by rapid resealing.

<span style=color:blue>CADY肽是首个二级两亲性CPP，由Crombez等人设计，含有20个氨基酸残基，旨在作为siRNA载体，其中包括精氨酸和色氨酸等氨基酸，以增强与siRNA及细胞膜脂质的相互作用。CADY的空间结构改进了其溶解性，并增强了其与siRNA的结合能力。据报告，使用CADY可以实现高达95%的基因抑制效果，同时细胞毒性较低或几乎没有细胞毒性。CADY:siRNA复合物的摄取似乎主要通过直接转运方式进行，且其并未与内吞标志物共定位，表明复合物的敲降效果不受内吞抑制剂的影响。电子显微镜观察发现，复合物主要分布在细胞质中，而不是在囊泡内，这进一步确认了CADY肽能够在不受内吞机制干扰的情况下发挥作用。CADY似乎能够引起短暂的膜结构改变，足够使其穿过细胞膜，随后膜会迅速自我修复。</span>

CADY-K is a CPP developed by Konate et al.  from the CADY sequence, as the name suggests, and showed a twofold increased knockdown of the target gene compared to the parental peptide. However, for the in vivo application, to avoid the degradation effects caused by extracellular and intracellular proteases, they developed a *retro-inverso* CADY K named RICK (***R***etro-***I***nverso  **C**ADY **K**)  that consists, in the reversed sequence, of D-amino acids instead of the L-isoforms. This strategy has been followed to obtain proteolytically stable peptide analogs that preserve the structural features essential to maintain the transfection properties of the peptide and the biological efficiency in vitro. Aldrian et al. reported the in vitro application of PEGylated RICK:siRNA complex, and also pharmacokinetic and biodistribution studies in vivo (on mouse and zebrafish). However, in vivo RICK:siRNA-induced knockdown has not yet been reported in the literature.

<span style=color:blue>CADY-K是Konate等人基于CADY肽序列开发的改良版本，其敲降目标基因的效果是原始肽的两倍。为了在体内应用中避免外部和内部蛋白酶的降解作用，研究者进一步开发了*retro-inverso* CADY K，即RICK（***R***etro-***I***nverso **C**ADY **K**），该肽的序列是反向的，且使用了D-氨基酸替代了L-氨基酸异构体。该策略的目的是开发出能够抵抗蛋白酶降解的稳定肽类，同时保持其转染效果和体外生物活性。Aldrian等人曾报道过PEG化的RICK:siRNA复合物在体外的应用，并进行了药代动力学和体内分布的研究（小鼠和斑马鱼模型）。然而，文献中尚未有关于RICK:siRNA在体内引起基因敲降的相关报道。</span>

Tat 49–57 (RKKRRQRRR)  opened the way for arginine-rich and homopolymers oligoarginine peptides. It was shown that oligoarginines can enter the cells more efficiently than other homopolymers and that the minimum length is around six residues. The most common length for oligoarginine peptides ranges between 7 and 9 residues. Exploiting the transfection proprieties of the polyarginine peptides in conjunction with the ability of hydrophobic moieties to compact the complexed carrier:cargo, CPP such as Chol-R9, a nonaarginine with a cholesteryl group conjugated to the N′ terminal, successfully delivered vascular endothelial growth factor (VEGF) targeting siRNA, inhibiting the production of VEGF in CT-26 cells in vitro and suppressing tumor growth in vivo. Similarly, stearyl-R8 complexed with siRNA reportedly efficiently reduced expression of the target gene in primary mammalian neurons with low toxicity, especially compared to commercial transfection agents such as Lipofectamine.

<span style=color:blue>Tat 49–57（RKKRRQRRR）为富含精氨酸的同聚物寡肽开辟了新的研究方向。研究表明，寡精氨酸肽的细胞进入效率高于其他类型的同聚物肽，其最小长度大约为6个氨基酸残基，通常使用的寡精氨酸肽的长度为7到9个氨基酸。通过利用多精氨酸肽的转染特性以及疏水基团帮助将载体和货物复合，Chol-R9（一种N端连接了胆固醇基团的九精氨酸肽）成功地递送了针对血管内皮生长因子（VEGF）的siRNA，抑制了CT-26细胞中VEGF的表达，并有效抑制了肿瘤的生长。同样，硬脂酸-R8与siRNA复合后，报告显示其能够在初级哺乳动物神经元中有效地降低目标基因的表达，且与商业转染试剂如Lipofectamine相比，其毒性较低</span>

In the last few years, a new stearylated peptide, STR-KV (STR-HHHKKKVVVVVV) has been developed and shown to cross the plasma membrane through a direct translocation pathway, achieving an 80% to 87% gene knockdown in three different cell lines. Huang et al. reported the use of a bifunctional peptide based on the arginine-glycine-aspartic acid (RGD) motif affinity for the integrin α<sub>v</sub>β<sub>3</sub>, highly expressed in tumor cells and neovascular endothelial cells, and the polyarginine R10. The bifunctional CPP is called RGD10-R10 where RGD10 is a cyclic RGD peptide that exhibits a higher affinity for αvβ3 than its linear version. RGD10-R10 showed a stronger siRNA binding capacity than naked R10, likely compromising the efficiency of siRNA effect. Indeed, in vivo experiments showed cellular internalization and tumor accumulation, but a low silencing effect in vitro that was likely due to a lack of endosomal escape or the failure of the complex to release the siRNA.

<span style=color:blue>最近，研究者开发了一种新的硬脂酰肽STR-KV（STR-HHHKKKVVVVVV），该肽能够通过直接转运方式跨越细胞膜，在三种不同的细胞系中实现了80%至87%的基因敲降。黄等人报告了使用基于精氨酸-甘氨酸-天冬氨酸（RGD）结构的双功能肽，该结构对肿瘤细胞和新生血管内皮细胞中高表达的整合素α<sub>v</sub>β<sub>3</sub>具有高亲和力，同时结合了多精氨酸R10。该双功能CPP被称为RGD10-R10，其中RGD10为环状肽，比线性版本的亲和力更高。RGD10-R10表现出比裸露R10更强的siRNA结合能力，但这可能影响了siRNA的效果。事实上，体内实验表明，尽管有细胞内化和肿瘤积累，但在体外的基因敲降效果较低，这可能是由于缺乏内吞逃逸或复合物未能释放siRNA。</span>

To enhance complex formation and trigger siRNA release inside the reducing environment cytoplasm, Tanaka et al. used a stearylated CPP, STR-CH2R4H2C (R: arginine, C: cysteine, H: histidine), wherein the cysteine’s thiol group is intended to stabilize the complexes by disulfide bonds between peptides, which is cleaved once inside the cell. A reduction of tumor growth after delivering siRNA for VEGF by direct tumor injection in mice was achieved. The CPP and siRNA complexes were obtained by simply mixing the two components at room temperature at different ratios and checking the degree of disulfide linkage in complexes using an Ellman’s reagent assay. The complexes were prepared by air oxidation to avoid excessive cross linkage that could decrease the release of siRNA from the carrier once in the cytoplasm.

<span style=color:blue>为了增强复合物的形成并触发siRNA在还原环境中的释放，Tanaka等人采用了一种硬脂酰化的CPP，STR-CH2R4H2C（其中R为精氨酸，C为半胱氨酸，H为组氨酸），其中半胱氨酸的硫醇基团通过二硫键稳定复合物，而这些二硫键在进入细胞后会被切断。他们通过直接将siRNA针对VEGF注射到小鼠肿瘤中，成功地抑制了肿瘤的生长。CPP和siRNA的复合物是通过将两种成分按不同的比例在室温下简单混合而成，并使用Ellman试剂测试复合物中的二硫键形成程度。为了避免过度交联影响siRNA的释放，复合物是通过空气氧化法制备的。</span>

To enhance the selectivity of a CPP, it can be equipped with a moiety that inhibits its ability to permeate the plasma membrane unless under certain environmental conditions. Indeed, the so-called “activatable CPPs” (aCPPs) are usually CPPs that expose their cationic domain only under certain conditions. Li et al.  used this strategy to deliver a plasmid encoding for the siRNA that targets human telomerase reverse transcriptase (hTERT) to reduce cell proliferation and inhibit cell growth. They used an activatable CPP (EEEEEEE-GALGLP-RRRRRRRRKKR) equipped with a polyglutamic acid domain able to neutralize the cationic charges of arginine/lysine sequence connected by a domain cleavable by the matrix metalloproteinase-2 (MMP2). MMPs are the most well-known proteases overexpressed by tumors, and most malignant tumors express MMP2. They succeeded in delivering the plasmid, which could occur only after cleavage of the polyglutamic acid, achieving a lower expression of hTERT. Despite the appeal of the “activatable” strategy, the delivery of proper siRNA by aCPPs is rarely reported.

<span style=color:blue>为了增强CPP的选择性，可以为其添加一个特殊的基团，使其只有在特定环境条件下才会穿透细胞膜。实际上，所谓的“可激活CPP”（aCPPs）通常只有在特定条件下才会暴露其阳离子部分。Li等人采用这一策略递送了一个针对人类端粒酶逆转录酶（hTERT）的siRNA质粒，从而降低细胞增殖并抑制细胞生长。他们设计了一个可激活的CPP（EEEEEEE-GALGLP-RRRRRRRRKKR），它包含一个聚谷氨酸基团，能够中和精氨酸/赖氨酸序列的阳离子电荷，并通过基质金属蛋白酶-2（MMP2）切割。MMP是肿瘤中过度表达的常见蛋白酶，大多数恶性肿瘤会过度表达MMP2。通过这种方法，他们成功递送了质粒，且这一过程仅在聚谷氨酸被切割后才会发生，从而实现了hTERT的低表达。尽管“可激活”策略非常具有吸引力，但通过aCPPs递送有效的siRNA的研究报告仍然较为稀少。</span>

The ability of a peptide to “distinguish” where or which kind of cells to enter seems to be mandatory for therapeutic application. Targeted delivery of siRNAs would reduce the amount of required drug, minimizing off-target effects. There are many examples of CPPs conjugated to antibodies to enhance the specificity of the delivery of the siRNA. Song et al. used the heavy chain Fab fragment of an HIV-1 envelope antibody fused to protamine (F105-P) to deliver siRNA specifically to cells expressing HIV-1 envelope via intravenous injection in mice. They went even further using an anti-ErbB2-protamine fusion protein to deliver siRNAs specifically to breast cancer cells. Penetratin:siRNA nanoparticles coated with hyaluronic acid (HA) have been developed as antiatherosclerotic therapy. These nanoparticles take advantage of the overexpression of CDD44 receptor by impaired endothelial cells and its affinity for the HA coating, which allows localization of the nanoparticles (NPs) in proximity to atherosclerotic lesions. Subsequently, the NPs diffuse through the permeable endothelium via the gaps between injured endothelial cells losing their HA coating due to the HAase within the plaques exposing the CPP:siRNA to the foam cells. These HA-coated NPs showed effective gene delivery into atherosclerotic plaques in vivo with an antiatherogenic efficacy dependent on HA molecular weight and coating density.

<span style=color:blue>肽能够“识别”特定细胞或细胞类型的能力似乎是治疗应用中的一个必要条件。siRNA的靶向递送可以减少所需药物的剂量，从而最小化不良反应。很多研究已经将CPP与抗体结合，以提高siRNA递送的特异性。例如，Song等人使用了HIV-1包膜抗体的重链Fab片段与精氨酸结合的F105-P融合蛋白，利用小鼠静脉注射将siRNA特异性地递送到表达HIV-1包膜的细胞。更进一步，他们采用了抗ErbB2-精氨酸融合蛋白，将siRNA专门递送到乳腺癌细胞。此外，包裹透明质酸（HA）的Penetratin:siRNA纳米粒子已被开发作为抗动脉粥样硬化的治疗方法。这些纳米粒子通过利用受损内皮细胞过度表达的CD44受体及其与透明质酸涂层的亲和力，将纳米粒子定位到动脉粥样硬化病变附近。随后，纳米粒子通过损伤的内皮细胞间隙扩散，透明质酸涂层在斑块内的HA酶作用下脱落，暴露出CPP:siRNA，进而被泡沫细胞摄取。这些透明质酸涂层的纳米粒子在体内有效递送基因到动脉粥样硬化斑块，并且其抗动脉粥样硬化效果与透明质酸的分子量和涂层密度相关。</span>

Homing peptides are molecules that can bind to specific sites in the vasculature in vivo. Screening for tumor homing peptides has produced a broad collection of peptides that localize in tumor tissues and that can be fused to CPPs and used to “aim” them at a specific tissue.

<span style=color:blue>归巢肽是能够在体内与血管特定部位结合的分子。通过筛选肿瘤归巢肽，已经得到了大量能够定位肿瘤组织的肽，并且这些肽可以与CPP融合，用于将CPP“导向”特定组织。</span>

Kumar and coworkers employed a short peptide derived from rabies virus glycoprotein (RVG), which can bind to the acetylcholine receptor expressed by neuronal cells, fused to a nonaarginine peptide (RVG-9R), and succeeded in RNAi silencing in vitro and in vivo after intravenous injection in mice. RVG-9R delivered siRNA to the neuronal cells, resulting in specific gene silencing within the brain. The same group performed an extensive study of siRNA transfection using nonaarginine (L and D) conjugated with different targeting ligands, evaluating the efficiency of transfection, mRNA knockdown, and uptake mechanism.

<span style=color:blue>Kumar及其同事利用从狂犬病毒糖蛋白（RVG）中提取的短肽，该肽能够与神经细胞中的乙酰胆碱受体结合，并将其与九精氨酸肽（RVG-9R）融合，成功地在小鼠体内外通过静脉注射实现了RNAi沉默。RVG-9R能够将siRNA递送到神经细胞，进而在大脑中实现特异性的基因沉默。同一研究小组还对使用九精氨酸（L型和D型）与不同靶向配体结合的siRNA转染进行了广泛研究，评估了转染效率、mRNA沉默和细胞摄取机制。</span>

In 2014, Youn et al. reported a myristic acid-conjugated transportan (TP)  equipped with a transferrin receptor-targeting peptide (myr-TP-Tf) that led to stable encapsulation and targeted delivery of functioning siRNA to brain endothelial cells, glioma cells, and across a model brain endothelial cell monolayer. Despite these encouraging results, and the development of novel CPP projected for targeted delivery, the use of siRNA in this area is rarely reported.

<span style=color:blue>2014年，Youn等人报告了一种肉豆蔻酸结合的转运肽（TP），该肽与转铁蛋白受体靶向肽（myr-TP-Tf）结合，成功地将siRNA稳定封装并靶向递送到脑血管内皮细胞、胶质瘤细胞，并能够穿过脑血管内皮细胞单层。尽管这些结果令人鼓舞，并且开发了新的CPP用于靶向递送，然而在这一领域中关于siRNA的使用报告却非常少。</span>

### 3.3 CPP-Decorated Multifunctional Nanocomplexes for siRNA Delivery CPP 修饰的多功能纳米复合物用于 siRNA 递送

Over the last few years, the number of reported siRNA delivery methods using combinations of CPPs and other carriers has increased. These decorated multifunctional nanocomplexes were developed to enhance selectivity, half-life in the bloodstream, and, more general, as a versatile tool exploiting the characteristics of several compounds simultaneously. Kang et al. used two different CPPs concurrently in the same delivery system. They modified their previously reported micelle-like nanoparticle (MNP) , named PLPEI, which is composed of a polyethylenimine (PEI) moiety that drives the formation of a dense polyplex core and a phospholipid (PL) moiety forming a surrounding lipid barrie. The replacement of the PEI moiety with a nonaarginine (R9) led to the so-called lipid-peptide hybrid nanoparticles (hNP) that are able to complex and carry oligonucleotides. The hNP has been further modified with Tat 48–60 to enhance cellular transfection (T-hNP). This last formulation has been reported to have a better accumulation in tumor tissue in vivo (mouse model), lasting for 72 h, and a better gene silencing effect.

<span style=color:blue>近年来，结合CPP与其他载体的siRNA递送方法数量有所增加。这些经过修饰的多功能纳米复合物旨在提高选择性、延长血液半衰期，并作为一种多功能工具，同时利用多种化合物的特性。Kang等人采用了两种不同的CPP，同时在同一递送系统中使用。他们对之前报道的类胶束纳米颗粒（MNP）进行了修改，命名为PLPEI，该颗粒由聚乙烯亚胺（PEI）基团和磷脂（PL）基团组成。PEI基团驱动密集多聚物核心的形成，PL基团则形成脂质屏障。用九精氨酸（R9）替代PEI基团后，得到了脂质-肽混合型纳米颗粒（hNP），这种颗粒能够复合并携带寡核苷酸。此hNP进一步通过Tat 48–60肽修饰，形成T-hNP，显著提高了细胞转染效率。该系统在小鼠肿瘤模型中表现出更好的肿瘤积累效果，并能够持续72小时，且具有更好的基因沉默效果。</span>

Harashima’s group in 2007, after screening different polycations, developed a stearylated octaarginine multifunctional envelope-type nano device  (R8-MEND) that inhibited luciferase activity more than 80% in HeLa cells expressing luciferase, showing minimal cytotoxicity. This delivery system has been developed even further via surface modification using GALA, a pH-sensitive fusogenic peptide that permits enhanced endosomal escape in response to the low pH in endosomes, and small unilamellar vesicles (SUV) that improve the intracellular uncoating, allowing RNA interference. The R8:GALA-MENDSUV showed more efficient gene knockdown than the regular R8:GALA-MEND in HeLa cells expressing GFP. R8:GALA-MENDSUV successfully reduced the expression of the suppressor of the cytokine signaling 1 (SOCS1) gene in primary mouse bone marrow-derived dendritic cells (BMDCs). Subsequently, the same group upgraded the R8-MEND system by equipping it with a PEG-peptide-lipid ternary conjugate (PEG-Peptide-DOPE conjugate (PPD)), which acts as a PEG-shield cleavable by the matrix metalloproteinases (MMPs) in the tumor tissue environment. After some optimization of the PEGylation ratio to find a balance between circulation time and silencing activity, the PPD-MEND accumulated in tumors and exhibited silencing activity, showing no hepatotoxicity and no immune system stimulation in vivo. Taking advantage of the mildly acidic pH in the tumor microenvironment, Xiang et al.  developed and characterized an activatable CPP-liposome-based siRNA delivery system. The DSPE-PEG2000 liposomes were decorated with an activatable CPP (DSPE-PEG2000-ACPP) composed of an octaarginine peptide connected to a polyanionic “shielding domain” composed of glutamate and histidine by means of an acid-labile linker (hydrazone). When exposed to the physiological pH (7.4), the cationic moiety of the CPP is “hidden” by the intramolecular electrostatic interaction with the glutamate in the polyanionic moiety, whereas when exposed to the lower microenvironmental pH of the tumor tissue, the linker is cleaved and the histidine in the “shielding domain” is protonated so the octaarginine is free to interact at the plasma membrane, allowing the modified liposomes to pass through and deliver the siRNA cargo.

<span style=color:blue>Harashima团队在2007年开发了肉豆蔻酸化的八精氨酸多功能包膜型纳米设备（R8-MEND），其能够在HeLa细胞中抑制超过80%的荧光素酶活性，且具有低细胞毒性。这一递送系统通过表面修饰进一步升级，采用了GALA肽，这是一种pH敏感的融合肽，能在低pH环境下促进内吞体逃逸，同时使用小单层囊泡（SUV）促进RNA干扰的内部分解。与常规R8:GALA-MEND相比，R8:GALA-MENDSUV显示出了更高效的基因沉默作用，并成功地降低了小鼠原代骨髓来源树突状细胞（BMDCs）中SOCS1基因的表达。随后，团队将PEG-肽-脂质三元共轭物（PPD）引入R8-MEND系统，成功优化了PEG化比例，在确保肿瘤积累的同时保持良好的基因沉默效果，在体内无肝毒性和免疫系统刺激反应。Xiang等人利用肿瘤微环境中的酸性pH，开发了一种可激活的CPP脂质体siRNA递送系统。该系统使用了酸敏感连接子（肼）将八精氨酸肽与多阴离子“屏蔽域”（由谷氨酸和组氨酸组成）连接，当暴露在低pH肿瘤微环境中时，连接子断裂，组氨酸质子化，从而使八精氨酸自由与细胞膜结合，促进脂质体进入细胞并递送siRNA负载。</span>

In 2010, Xiong et al. successfully developed a virus mimetic polymeric micelle for siRNA-targeted delivery based on poly(ethylene oxide)-block-poly(ɛ-caprolactone) (PEO-b-PCL) micelles decorated with integrin αvβ3 targeting peptide (RGD4C) and Tat peptide, and modified with a polycation (spermine) in the PCL core to bind and protect the siRNA. They also tested micelles decorated with just RGD4C or Tat, but the efficient cellular uptake and endosomal escape were observed only in the micelles possessing both peptides at the same time. Tat peptide was similarly used for the treatment of cardiovascular disease in the PCM-poly(CBA-DAH)-Tat polyplex developed by Nem et al. as a nonviral carrier for siRNA. Primary cardiomyocyte-specific peptide (PCM) has been used together with Tat and incorporated to the cystamine bisacrylamide-diaminohexane (CBA-DAH) polymer to achieve targeted siRNA transfection in cardiomyocytes, suppressing SHP-1 and Fas expression and decreasing cardiomyocyte apoptosis.

<span style=color:blue>2010年，Xiong等人成功研发了一种基于聚（乙烯醇）-块-聚（ɛ-己内酯）（PEO-b-PCL）胶束的病毒模拟聚合物，用于靶向递送siRNA，胶束表面同时修饰了RGD4C（整合素αvβ3靶向肽）和Tat肽，并且在PCL核心部分加入了聚阳离子（精氨酸），以结合和保护siRNA。他们还测试了分别只装饰了RGD4C或Tat的胶束，但只有同时拥有这两种肽的胶束才显示出有效的细胞摄取和内吞体逃逸效果。Tat肽也被应用于心血管疾病的治疗，Nem等人开发了PCM-poly(CBA-DAH)-Tat聚复合物，作为一种siRNA的非病毒载体。心肌细胞特异性肽（PCM）与Tat一起使用，并与半胱氨酸双丙烯酰胺-二氨基己烷（CBA-DAH）聚合物结合，用于靶向心肌细胞转染siRNA，成功抑制了SHP-1和Fas的表达，并减少了心肌细胞的凋亡。</span>

An interesting approach and results were achieved by Kim’s group starting from a simple nonaarginine peptide. They used a stepwise process of troubleshooting to overcome all the different barriers that the siRNA need to pass through to be effective. To solve the lack of specificity of the polyarginine peptide, it was fused with the tumor-homing peptide I4R, obtaining I4R-9r. They blended a small amount of an endosomolytic tandem peptide (sHGP-9r) with I4R-9r to enhance endosomal escape, and substituted alanine residues for one or more arginines along the polyarginine peptide sequence to determine the optimal balance between complex formation and cargo release in the cytoplasm. The final result was efficient gene silencing in vitro and in vivo by this so-called multicomponent peptide-woven siRNA nanocomplex (PwSN). A similar result was achieved by means of the previously described PF6, which was used to form complexes with siRNA that were loaded in lipid membrane capsules decorated with PF6 (PF6/PF6-NP). The potent RNA interference effect shown in vitro was likely achieved due to the high cellular uptake, the formation of loose complexes, and the facilitated endosomal escape due to the bulky quinoline moiety of PF6.

<span style=color:blue>Kim团队从简单的九精氨酸肽出发，通过逐步优化的过程克服了siRNA递送过程中的多个障碍，取得了有趣的进展。为了提高多精氨酸肽的特异性，他们将其与肿瘤靶向肽I4R融合，得到I4R-9r，并加入少量内吞体溶解串联肽（sHGP-9r）以增强内吞体逃逸效果。同时，他们通过用丙氨酸替代多精氨酸肽序列中的一个或多个精氨酸，来优化复合物的形成与载荷释放的平衡。最终，他们通过这种多组分肽编织siRNA纳米复合物（PwSN）成功实现了在体内外的高效基因沉默。类似的效果也通过之前提到的PF6系统实现，PF6与siRNA形成复合物，复合物被包裹在脂质膜胶囊中，表面装饰了PF6（PF6/PF6-NP）。这种系统通过促进内吞体逃逸及高效细胞摄取，展现了强大的RNA干扰效果。</span>

An interesting approach to target delivery in vivo is “ultrasound-mediated.” The application of ultrasound directly to the tumor tissue might trigger cargo delivery by some specifically designed carriers. One of the first steps in this direction was made by Ren et al., who wanted to selectively deliver pDNA in vivo by means of Tat peptide used to form the non-covalent complex with a pDNA that could adhere to the PEG4000 on the nanobubble surface. Later, searching for an “off-on” switch for nanocarriers, Xie et al. reported the development and use in vitro and in vivo of siRNA covalently conjugated to a CPP derived from penetratin, trapped in ultrasound-sensitive nanobubbles or nano-sized echogenic liposomes ((CPP-siRNA)-NB). They achieved efficient tumor accumulation of labeled siRNA exposed to ultrasound, accompanied by reduced liver accumulation, after systemic administration, and reduced tumor growth in vivo (in mice) compared to the “naked” CPP-siRNA and (CPP-siRNA)-NB not exposed to ultrasounds. The same penetratin-derived CPP covalently bonded to its siRNA cargo has been used in a dual stimulus delivery strategy based on the presence of homing peptide-decorated liposomes and hyperthermia. Higher accumulation and reduced tumor growth were reported after transfection of c-myc siRNA via CPP-siRNA conjugate encapsulated into thermosensitive liposomes (TSL) modified with homing moiety on the surface, compared to CPP-siRNA alone and the unheated CPP-siRNA/TSL.

<span style=color:blue>近年来，超声介导的靶向递送成为了一个有趣的研究方向。通过对肿瘤组织应用超声波，可能激活特定设计的载体来递送药物。Ren等人迈出了这一领域的第一步，使用Tat肽与pDNA形成非共价复合物，并将其附着到超声敏感的纳米气泡表面上的PEG4000，从而实现pDNA的靶向递送。Xie等人随后研究了利用“开关”激活纳米载体的可能性，开发了将siRNA共价连接到穿透肽衍生的CPP上，并将其困在超声敏感的纳米气泡或显像脂质体中的递送系统。他们发现，在使用超声波激活后，siRNA在肿瘤中的积累效果显著，肝脏的积累明显减少，且与“裸”CPP-siRNA和未暴露于超声波的（CPP-siRNA）-NB相比，肿瘤生长显著抑制。同样的穿透肽衍生的CPP与其siRNA载荷的共价结合也被应用于基于归巢肽装饰脂质体和超热疗法的双刺激递送策略，报告显示与单独的CPP-siRNA或未加热的CPP-siRNA/TSL相比，肿瘤积累增加且肿瘤生长得到有效抑制。</span>

Another strategy to “aim” at the tumor tissue via external stimulation is the use of a magnetic field and magnetic nanoparticles of Fe<sub>3</sub>O<sub>4</sub> as carriers. Qi et al. modified  Fe<sub>3</sub>O<sub>4</sub> nanoparticles with an amphipol polymer and a protamine peptide to form cell-penetrating magnetic nanoparticles (CPMNs), and reported eGFP expression suppressed to 12% in vitro under an applied external magnetic field. Recently, Ben Djemaa et al. reported the development of a siRNA delivery system based on PEGylated superparamagnetic iron oxide nanoparticles (SPION) functionalized with gH625 peptide, chitosan, and poly-L-arginine. In this strategy, SPIONs are intended to serve as scaffolding, and the PEG as a “shield” in the bloodstream, wherein the cationic peptide should enhance complex formation with the siRNA and the endosomal escape and gH625 should guarantee internalization through the plasma membrane. They reported an efficient downregulation of eGFP in vitro and, with further studies, expanded on the role gH625 may play in endosomal escape as well as in the internalization step in a triple-negative breast cell line.

<span style=color:blue>另一种通过外部刺激靶向肿瘤的策略是利用磁场和磁性纳米粒子（ Fe<sub>3</sub>O<sub>4</sub>）作为载体。Qi等人开发了磁性纳米粒子（CPMNs），通过两性聚合物和原蛋白肽修饰，报告了在施加外部磁场的条件下，eGFP的表达在体外被有效抑制。Ben Djemaa等人最近也开发了一种基于PEG化超顺磁性氧化铁纳米粒子（SPION）的siRNA递送系统，SPION被功能化了gH625肽、壳聚糖和聚-L-精氨酸，在该策略中，SPION充当支架，PEG作为血液中的“屏障”，而阳离子肽则促进了siRNA的复合物形成和内吞体逃逸，gH625肽确保通过细胞膜的内化。他们报告了在体外eGFP的有效下调，进一步研究了gH625在内吞体逃逸和内化过程中的作用，特别是在三阴性乳腺癌细胞系中的表现。</span>

To use different triggers at the same time, a photo-pH-responsive polypeptide (PPP) , used to decorate poly(lactic-co-glycolic acid) (PLGA) nanoparticles, has been developed and its selective siRNA transfection capacity has been evaluated in vitro and in vivo. The PPP is composed of three different elements: a penetratin-derived CPP, a photo-degradable group (4,5-dimethoxy-2-nitrobenzyl), and a pH-sensitive inhibitory peptide. The idea behind this system is to expose the tumor site to near infrared (NIR) to cleave the photo-degradable group and exploit the lower pH of the tumor environment to expose the CPP, which will be free to transfect the nanoparticle through the plasma membrane and deliver the siRNA in the cytoplasm. Accumulation and reduced tumor growth has been reported in a mouse model using this dual-stimuli responsive nanoparticle system.

<span style=color:blue>此外，针对肿瘤组织的双刺激递送策略也得到了开发。通过将光pH响应型多肽（PPP）用于修饰PLGA纳米粒子，研究人员在体外和体内评估了其siRNA转染能力。PPP由穿透肽衍生的CPP、光降解基团和pH敏感的抑制肽组成。系统的设计理念是，通过近红外光（NIR）激活光降解基团，并利用肿瘤微环境的低pH暴露CPP，从而使CPP能够自由地穿透细胞膜并将siRNA递送至细胞质中。使用这种双刺激响应型纳米粒子系统的鼠模型报告了更高的积累效果和肿瘤生长的显著抑制。</span>

## 4 Conclusions 结论

In this overview, many ideas to develop and apply different siRNA delivery methods using CPPs have been reported (Table 1). These two promising technologies and the current lack of clinical applications suggest that their combined use might overcome their individual shortcomings (Fig. 3). Similarly, developing multifunctional nanoparticles that exploit CPPs, polymers, lipids, antibodies at the same time and any other tool to protect and selectively deliver siRNA seems to be the right path to follow to finally develop a clinically efficient RNA interference-based therapy. Given the fundamental role of CPPs in passing through the plasma membrane, more research is needed to increase the number of available peptides, to fully understand their mechanisms of uptake and endosomal escape to achieve a complete picture of their possibilities and limitations and thus identify the best CPP, or CPPs to most effectively deliver the cargo for the given conditions until full clinical application.

<span style=color:blue>本文概述了多种利用细胞穿透肽（CPPs）开发和应用不同siRNA递送方法的研究进展（见表1）。这两种有前景的技术，以及目前缺乏临床应用的现状，表明将它们结合使用可能有助于克服各自的局限性（见图3）。同样，开发结合CPPs、聚合物、脂质、抗体等多种成分的多功能纳米粒子，旨在同时保护并选择性递送siRNA，似乎是最终实现临床有效的RNA干扰治疗的正确途径。考虑到CPPs在细胞膜穿透中的关键作用，还需要进一步研究，以扩大可用的CPP种类，全面了解其摄取机制和内吞体逃逸机制，深入探索它们的优势与限制，进而筛选出最适合在特定条件下递送siRNA的最佳CPP，推动其最终应用于临床。</span>

**Table 1** Summary of different uses of CPPs for siRNA delivery in vitro and in vivo

<table style="width:100.0%;background:white;border-collapse:collapse;border:none;">
    <thead>
        <tr>
            <td style="width: 29.26%;border: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><strong><span style="color:black;">CPP</span></strong></p>
            </td>
            <td style="width: 70.74%;border-top: 1pt solid windowtext;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-image: initial;border-left: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><strong><span style="color:black;">Delivery strategy</span></strong></p>
            </td>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td colspan="2" style="width: 100%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><em><span style="color:black;">Covalent bond (CPP-siRNA)</span></em></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Penetratin</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Cleavable disulfide linkage</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Tat (48&ndash;600</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Cleavable disulfide linkage</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Penetratin</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Cargo linked to the 3&prime; end</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Tat (48&ndash;60)</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Linked to the 3&prime; end</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Tat (47&ndash;57)</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Non-cleavable linker</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">LMW protamine</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">PEG spacer</span></p>
            </td>
        </tr>
        <tr>
            <td colspan="2" style="width: 100%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><em><span style="color:black;">Non-covalent complex (CPP:siRNA)</span></em></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">TatU1A</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">RNA binding sequence</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Tat-dsRBD; Hph1-Hph1-dsRBD; Tat-Tat-Tat-dsRBD</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">siRNA binding moiety (dsRNA binding domain)</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">EB1</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Alpha helix structure in acidic pH</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">PepFect6 (PF6)</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">pH-sensitive trifluoromethylquinoline moiety</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">PepFect14 (PF14)</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Ornithines as source of positive charges</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">PF14:TG1</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">TG1 as targeting peptide for human glioblastoma cells</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">NickFect70 (NF70)</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Polyhistidine sequence which works as pH-sensitive switch</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">CADY</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Secondary amphipathic CPP</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">CADY-K</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Shorter version of CADY</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">RICK</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Reversed sequence of D-amino acids of CADY-K</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Chol-R9</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">N&prime; cholesteryl group</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Stearyl-R8</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">N&prime; stearyl group</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">STR-KV</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Three different moieties each one with a specific role in the delivery</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">RGD10-R10</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">RGD motif affinity for the integrin &alpha;<sub>v</sub>&beta;<sub>3</sub></span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">STR-CH2R4H2C</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Disulfide crosslinked complexes</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">EEEEEEE-GALGLP-RRRRRRRRKKR</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">CPP activatable by MMP2</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">F105-P</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Selective delivery to HIV-1 expressing cells</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">F5-P</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Selective delivery to breast cancers cells</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">scFvCD7-9R</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Selective delivery to HIV infected cells</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">hu3S193-9R</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Poly-D-arginine selectively targets Ley-expressing tumors</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Penetratin</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Coated with hyaluronic acid for selective localization</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">RVG-R9</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Selectively bind to acetylcholine receptor expressed by neuronal cells</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Myr-TP-Tf</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Transportan conjugated to transferrin receptor target peptide</span></p>
            </td>
        </tr>
        <tr>
            <td colspan="2" style="width: 100%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><em><span style="color:black;">Multifunctional nanocomplexes</span></em></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">R9 and Tat</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Micelle-like nanoparticle decorated with R9 and Tat</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">R8</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Envelope-type nano-device decorated with R8</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">R8</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Small unilamellar vesicles endowed with a pH-sensitive fusogenic peptide to enhance endosomal escape</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">R8</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">R8-MEND equipped with a PEG-shield cleavable by MMPs</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">R8</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Modified liposomes decorated with R8 activatable in low pH environment</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Tat</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Micelles decorated with Tat peptide and integrin &alpha;<sub>v</sub>&beta;<sub>3</sub> targeting peptide (RGD4C)</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Tat</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Cardiomyocyte specific delivery</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">R9</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Multicomponent peptide-woven siRNA nanocomplex based of homing and endosomolytic peptides and nonaarginine</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">PF6</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">PF6:siRNA coated by lipid membranes decorated with PF6</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Penetratin</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">CPP-siRNA trapped in ultrasound-sensitive nanobubbles</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Penetratin</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Penetratin:siRNA in CPP:siRNA/TSL (thermosensitive liposomes)</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Protamine</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">Cell-penetrating magnetic nanoparticles (CPMNs)</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">gH625</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">SPION nanoparticles equipped with gH625</span></p>
            </td>
        </tr>
        <tr>
            <td style="width: 29.26%;border-right: 1pt solid windowtext;border-bottom: 1pt solid windowtext;border-left: 1pt solid windowtext;border-image: initial;border-top: none;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">CGRRMKWKK</span></p>
            </td>
            <td style="width: 70.74%;border-top: none;border-left: none;border-bottom: 1pt solid windowtext;border-right: 1pt solid windowtext;padding: 4.5pt;vertical-align: top;">
                <p style="margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:15px;font-family:等线;"><span style="color:black;">CPP conjugated to a photo-pH-responsive polypeptide (PPP) loaded with the siRNA</span></p>
            </td>
        </tr>
    </tbody>
</table>

![485053_1_En_18_Fig3_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_18_Fig3_HTML.png)

**Fig. 3** Overall view of the uptake mechanism and siRNA silencing pathway